New horizons in cellular immunotherapy

CELL AND GENE THERAPY INSIGHTS

August 2022

New horizons in cellular immunotherapy

Download PDF

Expert Insight

CAR T cell immunotherapy of epithelial ovarian cancer: past, present and a view of the horizon

CAR T cell immunotherapy of epithelial ovarian cancer: past, present and a view of the horizon

Jana Obajdin, John Maher

Interview

Advancing genome edited allogeneic cell therapies into the clinic

Advancing genome edited allogeneic cell therapies into the clinic

Ensuring commercial readiness in the cellular cancer immunotherapy space

Ensuring commercial readiness in the cellular cancer immunotherapy space

Julian Adams, Michele Korfin, Ronit Simantov

Podcast

Working together to safely advance cell & gene therapies

Working together to safely advance cell & gene therapies

J Maher, A J King, F Neethling et al.

12 September 2022

Expert Roundtable

Autologous versus allogeneic: the future of manufacturing and standardization in cell therapies

Autologous versus allogeneic: the future of manufacturing and standardization in cell therapies

Rupa Pike, Delara Motlagh, Patrick Hanley

FastFacts

Scalable production of lipid nanoparticles for effective gene delivery

Scalable production of lipid nanoparticles for effective gene delivery

12 October 2022

Viewpoint

<em>In vivo</em> engineering of CAR T cell therapies

In vivo engineering of CAR T cell therapies

Haig Aghajanian

A journey in synthetic biology: using gene circuit technology in immuno-oncology

A journey in synthetic biology: using gene circuit technology in immuno-oncology

Timothy Lu, James Collins

The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

Dr Wei Li, Dr Daniel Teper